Literature DB >> 28123582

ETS-related gene is a novel prognostic factor in childhood acute lymphoblastic leukemia.

Hai-Zhao Zhao1, Ming Jia1, Ze-Bin Luo1, Xiao-Jun Xu1, Si-Si Li1, Jing-Ying Zhang1, Xiao-Ping Guo1, Yong-Min Tang1.   

Abstract

The ETS-related gene (ERG) has been demonstrated to be associated with overall survival in cytogenetically normal acute myeloid leukemia and acute T cell-lymphoblastic leukemia (T-ALL) in adult patients. However, there are no data available regarding the impact of ERG expression on childhood ALL. In the present study, ERG expression levels were analyzed in bone marrow samples from 119 ALL pediatric patients. ALL patients demonstrated higher ERG expression compared with the controls (P<0.0001). In addition, low ERG expression identified a group of patients with higher white blood cell counts (P=0.011), higher percentages of T-ALL immunophenotype (P=0.027), and higher relapse rates (P=0.009). Survival analyses demonstrated that low ERG expression was associated with inferior relapse-free survival (RFS) in childhood ALL (P=0.036) and was an independent prognostic factor in multivariable analyses for RFS. In conclusion, low ERG expression is associated with poor outcomes and may be used to serve as a molecular prognostic marker to identify patients with a high risk of relapse in childhood ALL.

Entities:  

Keywords:  ERG; acute lymphoblastic leukemia; childhood; prognosis; relapse

Year:  2016        PMID: 28123582      PMCID: PMC5245103          DOI: 10.3892/ol.2016.5397

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  30 in total

1.  Day 22 of induction therapy is important for minimal residual disease assessment by flow cytometry in childhood acute lymphoblastic leukemia.

Authors:  Xiao-Jun Xu; Yong-Min Tang; Hong-Qiang Shen; Hua Song; Shi-Long Yang; Shu-Wen Shi; Wei-Qun Xu
Journal:  Leuk Res       Date:  2012-04-05       Impact factor: 3.156

2.  [Recommendations for diagnosis and treatment of acute lymphoblastic leukemia in childhood (3rd revised version)].

Authors: 
Journal:  Zhonghua Er Ke Za Zhi       Date:  2006-05

3.  The clinical relevance of BAALC and ERG expression levels in pediatric AML.

Authors:  M C H Hermkens; M M van den Heuvel-Eibrink; S T C J M Arentsen-Peters; A Baruchel; J Stary; D Reinhardt; M Zimmerman; V de Haas; R Pieters; C M Zwaan
Journal:  Leukemia       Date:  2012-08-16       Impact factor: 11.528

4.  A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol.

Authors:  Marco Mancini; Daniela Scappaticci; Giuseppe Cimino; Mauro Nanni; Valentina Derme; Loredana Elia; Agostino Tafuri; Marco Vignetti; Antonella Vitale; Antonio Cuneo; Gianluigi Castoldi; Giuseppe Saglio; Fabrizio Pane; Cristina Mecucci; Andrea Camera; Giorgina Specchia; Alessandra Tedeschi; Francesco Di Raimondo; Giuseppe Fioritoni; Francesco Fabbiano; Filippo Marmont; Felicetto Ferrara; Nicola Cascavilla; Giuseppe Todeschini; Francesco Nobile; Maria Grazia Kropp; Pietro Leoni; Antonio Tabilio; Mario Luppi; Luciana Annino; Franco Mandelli; Robin Foà
Journal:  Blood       Date:  2005-01-13       Impact factor: 22.113

5.  Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.

Authors:  Guido Marcucci; Claudia D Baldus; Amy S Ruppert; Michael D Radmacher; Krzysztof Mrózek; Susan P Whitman; Jonathan E Kolitz; Colin G Edwards; James W Vardiman; Bayard L Powell; Maria R Baer; Joseph O Moore; Danilo Perrotti; Michael A Caligiuri; Andrew J Carroll; Richard A Larson; Albert de la Chapelle; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2005-11-07       Impact factor: 44.544

6.  BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Authors:  Sebastian Schwind; Guido Marcucci; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Kelsi B Holland; Dean Margeson; Heiko Becker; Susan P Whitman; Yue-Zhong Wu; Klaus H Metzeler; Bayard L Powell; Jonathan E Kolitz; Thomas H Carter; Joseph O Moore; Maria R Baer; Andrew J Carroll; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  Blood       Date:  2010-09-14       Impact factor: 22.113

7.  Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome.

Authors:  Richard C Harvey; Charles G Mullighan; Xuefei Wang; Kevin K Dobbin; George S Davidson; Edward J Bedrick; I-Ming Chen; Susan R Atlas; Huining Kang; Kerem Ar; Carla S Wilson; Walker Wharton; Maurice Murphy; Meenakshi Devidas; Andrew J Carroll; Michael J Borowitz; W Paul Bowman; James R Downing; Mary Relling; Jun Yang; Deepa Bhojwani; William L Carroll; Bruce Camitta; Gregory H Reaman; Malcolm Smith; Stephen P Hunger; Cheryl L Willman
Journal:  Blood       Date:  2010-08-10       Impact factor: 22.113

8.  ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.

Authors:  Klaus H Metzeler; Annika Dufour; Tobias Benthaus; Manuela Hummel; Maria-Cristina Sauerland; Achim Heinecke; Wolfgang E Berdel; Thomas Büchner; Bernhard Wörmann; Ulrich Mansmann; Jan Braess; Karsten Spiekermann; Wolfgang Hiddemann; Christian Buske; Stefan K Bohlander
Journal:  J Clin Oncol       Date:  2009-09-14       Impact factor: 44.544

9.  Human ERG is a proto-oncogene with mitogenic and transforming activity.

Authors:  A H Hart; C M Corrick; M J Tymms; P J Hertzog; I Kola
Journal:  Oncogene       Date:  1995-04-06       Impact factor: 9.867

10.  Precise developmental regulation of Ets family transcription factors during specification and commitment to the T cell lineage.

Authors:  M K Anderson; G Hernandez-Hoyos; R A Diamond; E V Rothenberg
Journal:  Development       Date:  1999-06       Impact factor: 6.868

View more
  1 in total

1.  Unexpected suppression of tumorigenesis by c-MYC via TFAP4-dependent restriction of stemness in B lymphocytes.

Authors:  Elena Tonc; Yoshiko Takeuchi; Chun Chou; Yu Xia; Melanie Holmgren; Chika Fujii; Saravanan Raju; Gue Su Chang; Masahiro Iwamoto; Takeshi Egawa
Journal:  Blood       Date:  2021-12-16       Impact factor: 25.476

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.